NLS Pharmaceutics Ltd. (NLSP)
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
Address
THE CIRCLE 6
ZURICH, V8 CH-6370
Founded
2015
Number of Employees
4
Website
http://www.nlspharma.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)